Personalis Price to Sales Ratio 2018-2024 | PSNL

Historical PS ratio values for Personalis (PSNL) over the last 10 years. The current P/S ratio for Personalis as of November 01, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Personalis P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-11-01 5.09 3.18
2024-06-30 1.17 $1.60 0.73
2024-03-31 1.49 $1.52 0.98
2023-12-31 2.10 $1.50 1.40
2023-09-30 1.21 $1.41 0.86
2023-06-30 1.88 $1.44 1.31
2022-12-31 1.98 $1.43 1.39
2022-09-30 2.97 $1.53 1.94
2022-06-30 3.45 $1.71 2.02
2022-03-31 8.19 $1.80 4.54
2021-12-31 14.27 $2.05 6.95
2021-09-30 19.24 $2.14 8.99
2021-03-31 24.61 $2.25 10.92
2020-12-31 36.61 $2.37 15.44
2020-09-30 21.67 $2.79 7.76
2020-06-30 12.97 $2.73 4.76
2020-03-31 8.07 $2.66 3.03
2019-12-31 10.90 $4.45 2.45
2021-06-30 25.30 $3.85 6.58
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.270B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00